Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.

Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ

Open source

DOI: 10.1016/j.ccell.2023.04.008
Published: 2023 Jun 12
Container: Cancer cell
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ccell.2023.04.008,
  title = {Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.},
  author = {Magbanua MJM and Brown Swigart L and Ahmed Z and Sayaman RW and Renner D and Kalashnikova E and Hirst GL and Yau C and Wolf DM and Li W and Delson AL and Asare S and Liu MC and Albain K and Chien AJ and Forero-Torres A and Isaacs C and Nanda R and Tripathy D and Rodriguez A and Sethi H and Aleshin A and Rabinowitz M and Perlmutter J and Symmans WF and Yee D and Hylton NM and Esserman LJ and DeMichele AM and Rugo HS and van 't Veer LJ},
  year = {2023},
  journal = {Cancer cell},
  doi = {10.1016/j.ccell.2023.04.008},
  url = {https://doi.org/10.1016/j.ccell.2023.04.008}
}

RIS

TY  - JOUR
TI  - Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
AU  - Magbanua MJM
AU  - Brown Swigart L
AU  - Ahmed Z
AU  - Sayaman RW
AU  - Renner D
AU  - Kalashnikova E
AU  - Hirst GL
AU  - Yau C
AU  - Wolf DM
AU  - Li W
AU  - Delson AL
AU  - Asare S
AU  - Liu MC
AU  - Albain K
AU  - Chien AJ
AU  - Forero-Torres A
AU  - Isaacs C
AU  - Nanda R
AU  - Tripathy D
AU  - Rodriguez A
AU  - Sethi H
AU  - Aleshin A
AU  - Rabinowitz M
AU  - Perlmutter J
AU  - Symmans WF
AU  - Yee D
AU  - Hylton NM
AU  - Esserman LJ
AU  - DeMichele AM
AU  - Rugo HS
AU  - van 't Veer LJ
PY  - 2023
JO  - Cancer cell
DO  - 10.1016/j.ccell.2023.04.008
UR  - https://doi.org/10.1016/j.ccell.2023.04.008
ER  -

APA

MJM, M., L, B. S., Z, A., RW, S., D, R., E, K., GL, H., C, Y., DM, W., W, L., AL, D., S, A., MC, L., K, A., AJ, C., A, F., C, I., R, N., D, T., A, R., H, S., A, A., M, R., J, P., WF, S., D, Y., NM, H., LJ, E., AM, D., HS, R., & LJ, V. '. V. (2023). Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.. Cancer cell. https://doi.org/10.1016/j.ccell.2023.04.008

Source records

pubmed · retrieved 2026-09-27T01:07:10.088Z